A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Efficacy and Safety of CAM-3001 in Subjects With Rheumatoid Arthritis
Sponsor: MedImmune LLC
Listed as NCT01050998, this PHASE2 trial focuses on Rheumatoid Arthritis and remains completed. Sponsored by MedImmune LLC, it has been updated 8 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jul 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jan 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MedImmune LLC
- MedImmune Ltd
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barnaul, Russia , Bialystok, Poland , Bruntál, Czechia , Bucharest, Romania , Budapest, Hungary , Bydgoszcz, Poland , Chiba, Japan , Chiyoda-ku, Japan , Donetsk, Ukraine , Fukui-shi, Japan and 45 more locations